SCHEMBL1110201

SCHEMBL1110201

CC(C(=O)O)N(c1ccc2c(C(=O)NCc3ccc(CNC(=O)OC(C)(C)C)cc3)cccc2c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLA1 P09884 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
KCNA5 P22460 1/20 0.35
ACACB O00763 1/20 0.35
ACACA Q13085 1/20 0.35
NTSR1 P30989 1/20 0.35
MAPT P10636 1/20 0.35
RECQL P46063 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110200 0.91 POLA1 (0.34) POLA1KMT2AMEN1NPSR1HDAC1
SCHEMBL1319036 0.90 KCNA5 (0.41) POLA1KMT2AMEN1KCNA5HDAC1
SCHEMBL1320168 0.89 POLA1 (0.39) POLA1KMT2AMEN1KCNA5NPSR1
SCHEMBL1110380 0.86 AKR1B1 (0.40) POLA1HDAC1HDAC3HDAC4HDAC7
SCHEMBL4241496 0.86 KEAP1 (0.39) POLA1KMT2AACACBACACAHDAC1
Hydrochloric Acid SCHEMBL1110586 0.85 HDAC2 (0.40) POLA1HDAC1HDAC3HDAC4HDAC7
SCHEMBL12119299 0.84 KMT2A (0.38) POLA1KMT2AL3MBTL1HDAC1HDAC3
SCHEMBL12119338 0.79 TUBB (0.44) POLA1KMT2AMEN1L3MBTL1KCNA5
SCHEMBL4241494 0.78 KEAP1 (0.36) POLA1MAPTNPSR1HDAC1HDAC3
SCHEMBL12119699 0.77 RORC (0.42) KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed
EP-2279173-A1 NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 POLA1 3199/4885KMT2A 645/4885MEN1 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.